LLY SEC Filings
SEC filings for LLY. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-QAIEli Lilly reports exceptional growth (revenue +39% in the quarter, +46% year to date) driven by incretin demand and a strong pipeline, with positive regulatory milestones. | Oct 29, 2026 | 0000059478-26-000108EDGAR |
| 10-Q | Aug 5, 2026 | 0000059478-26-000081EDGAR |
| 10-QAIEli Lilly reports exceptional Q1 2026 results (revenue +56%, net income +168%) and strong pipeline progress, including the FDA approval of Foundayo. | Apr 30, 2026 | 0000059478-26-000045EDGAR |
SEC filings for companies related to LLY
Never miss a LLY filing.
Get an email when LLY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.